AbbVie Inc. (NYSE:ABBV) is well-positioned to deliver a top-tier long-term outlook, driven by Humira’s success and strategic ...

The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

Here is our list of the 15 unhealthiest countries in Latin America.

The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...

Maggie Smith, acting legend of 'Harry Potter' and 'Downton Abbey' fame, dies at 89 Aerial footage shows extensive Helene ...

AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...